首頁 > 市場調查報告書 > 製藥

癌症生物標記

市場調查報告書

商品編碼

1461319

癌症生物標記市場，依生物標記類型，依癌症類型，依分析技術，依最終用戶，依地理位置

Cancer Biomarkers Market, By Biomarker Type, By Cancer Type, By Profiling Technology, By End User, By Geography

出版日期: 2024年03月22日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球癌症生物標記市場價值為256億美元，預計到2031年將達到590.1億美元，2024年至2031年年複合成長率（CAGR）為12.7%。

報告範圍		報告詳情
基準年：	2023年	2023/2024 年市場規模：	256億美元
歷史數據：	2019年至2023年	預測期：	2024年至2031年
預測期間 2023/2024 至 2030/2031 年複合成長率：	12.70%	2030/2031 價值預測：	590.1 億美元

癌症生物標記市場佔有率 (%)（依地區），2024 年

癌症生物標記是在血液、組織或其他體液中發現的生物分子，是正常或異常過程、狀況或疾病的標誌。這些可用於檢測和監測癌症或癌症進展。近年來，癌症生物標記引起了全球公共和私人組織的極大關注，因為它們提供了診斷、分期和追蹤癌症的微創方法。它們的使用也使腫瘤學家能夠根據個別患者的癌症概況進行個人化治療。基因分析和高通量技術的進步釋放了生物標記的潛力，可以更準確地預測治療反應和疾病進展。這對於改善全球癌症護理具有廣闊的前景。

市場動態：

全球癌症生物標記市場的成長是由全球癌症盛行率上升、精準醫療和伴隨診斷的日益普及以及生物標記在藥物開發和核准中的使用不斷增加所推動的。然而，與生物標記發現、驗證和商業化相關的高成本構成了課題。此外，技術限制和缺乏報銷限制了市場的成長。市場見證了癌症人口眾多且醫療支出不斷成長的新興經濟體帶來的利潤豐厚的機會。進一步的機會在於透過持續的研究工作發現新的生物標記物，特別是針對難以治療的癌症。

研究的主要特點：

該報告對全球癌症生物標記市場進行了深入分析，並提供了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。
它闡明了不同區隔市場的潛在收入機會，並解釋了該市場有吸引力的投資主張矩陣。
這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
它根據以下參數描述了全球癌症生物標記市場的主要參與者——公司亮點、產品組合、主要亮點、財務表現和策略。
該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球癌症生物標記市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
利害關係人可以透過用於分析全球癌症生物標記市場的各種策略矩陣輕鬆做出決策。

介紹
北美洲
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地區
歐洲
英國
德國
義大利
法國
西班牙
俄羅斯
歐洲其他地區
亞太地區
中國
印度
日本
東協
澳洲
韓國
亞太地區其他地區
中東
海灣合作理事會
以色列
中東其他地區
非洲
北非
中非
南非

第 10 章：競爭格局

bioMerieux, Inc.
INOVIQ
Bio-Rad Laboratories, Inc.
Abbott
Becton, Dickinson and Company
Merck KGaA
QIAGEN
Thermo Fisher Scientific Inc.
CENTOGENE N.V.
PerkinElmer Inc.
Siemens Healthineers
F. Hoffmann-la Roche Ltd
Agilent Technologies, Inc
Invitae Corporation
Myriad Genetics
Guardant Health
Illumina
FOUNDATION MEDICINE, INC.

第 11 章：分析師觀點

命運之輪
分析師觀點
連貫的機會圖

第 12 章：參考文獻與研究方法

參考
研究方法論

簡介目錄

Product Code: CMI175

Global cancer biomarkers market is estimated to be valued at USD 25.60 Bn in 2024 and is expected to reach USD 59.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 25.60 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	12.70%	2030/2031 Value Projection:	US$ 59.01 Bn

Cancer Biomarkers Market Share (%), By Region, 2024

Cancer biomarkers are biological molecules found in blood, tissues or other body fluids that are sign of a normal or abnormal process, or of a condition or disease. These can be used to detect and monitor cancer or cancer progression. In recent years, cancer biomarkers have gained significant attention from both global public and private organizations as these present minimally invasive ways to diagnose, stage and track cancer. Their use also enables oncologists to personalize treatments based on individual patient's cancer profiles. Advancements in genetic profiling and high-throughput technologies have unlocked the potential of biomarkers that can predict treatment responses and disease progression more accurately. This has promising implications for improving cancer care globally.

Market Dynamics:

Global cancer biomarkers market growth is driven by rising cancer prevalence worldwide, increasing popularity of precision medicine and companion diagnostics, and growing use of biomarkers in drug development as well as approvals. However, high costs associated with biomarker discovery, validation, and commercialization pose a challenge. Moreover, technical limitations and lack of reimbursements restrain the market growth. The market witnesses lucrative opportunities from emerging economies with large cancer populations and growing health expenditures. Further opportunities lie in discovery of novel biomarkers especially for hard-to-treat cancers through ongoing research efforts.

Key Features of the Study:

This report provides in-depth analysis of the global cancer biomarkers market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cancer biomarkers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study includes bioMerieux Inc., INOVIQ, Bio-Rad Laboratories Inc., Abbott, Becton Dickinson and Company, Merck KGaA, QIAGEN N.V., Thermo Fisher Scientific Inc., CENTOGENE N.V., PerkinElmer Inc., Siemens Healthineers, F. Hoffmann-la Roche Ltd, Agilent Technologies, Inc, Invitae Corporation, Myriad Genetics, Guardant Health, Illumina, and FOUNDATION MEDICINE, INC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global cancer biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer biomarkers market

Detailed Segmentation-

Biomarker Type:
- CA 125
- HER2
- EGFR
- CD20
- BRAF
- Calcitonin
- Others
Cancer Type:
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Kidney Cancer
- Liver Cancer
- Head & neck Cancer
- Non-small Cell Lung Cancer
- Other Cancers
Profiling Technology:
- OMICS Technology
- Imaging Technology
- Immunoassays
- Cytogenetics
- Others
End User:
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Academic Research Institutes
- Others
Regional:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- bioMerieux Inc.
- INOVIQ
- Bio-Rad Laboratories Inc.
- Abbott
- Becton Dickinson and Company
- Merck KgaA
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- CENTOGENE N.V.
- PerkinElmer Inc.
- Siemens Healthineers
- Hoffmann-la Roche Ltd
- Agilent Technologies, Inc
- Invitae Corporation
- Myriad Genetics
- Guardant Health
- Illumina
- FOUNDATION MEDICINE, INC.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Biomarker Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Profiling Technology
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
PEST Analysis

4. Global Cancer Biomarkers Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Impact on Supply and Demand
COVID-19 Impact on the market

5. Global Cancer Biomarkers Market, By Biomarker Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
CA 125
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
HER2
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
EGFR
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
CD20
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
BRAF
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Calcitonin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Cancer Biomarkers Market, By Cancer Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Breast Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Prostate Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Kidney Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Liver Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Head & neck Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Non-small Cell Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Other Cancers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Cancer Biomarkers Market, By End User, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
OMICS Technology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Imaging Technology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Immunoassays
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Cytogenetics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Cancer Biomarkers Market, By End User, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Specialty Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Diagnostic Laboratories
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Academic & Research Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

9. Global Cancer Biomarkers Market, By Region, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
North Africa
Central Africa
South Africa

10. Competitive Landscape

bioMerieux, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
INOVIQ
Bio-Rad Laboratories, Inc.
Abbott
Becton, Dickinson and Company
Merck KGaA
QIAGEN
Thermo Fisher Scientific Inc.
CENTOGENE N.V.
PerkinElmer Inc.
Siemens Healthineers
F. Hoffmann-la Roche Ltd
Agilent Technologies, Inc
Invitae Corporation
Myriad Genetics
Guardant Health
Illumina
FOUNDATION MEDICINE, INC.